PROTAC bottleneck breakthroughs

The newest set of intracellular PROTACs are engineered to control where they act, how long they persist, and which ubiquitin ligases they co‑opt to degrade proteins, with a flood of innovations coming out of Chinese labs.

Clinical experiences with the first wave of PROTACs (proteolysis targeting chimeras) suggest the chimeric modality is successfully degrading proteins in patients, but there are limitations related to PK, toxicity, and target space...